Psilocybin fMRI Study Initiated for Major Depressive Disorder
An open-label fMRI study is assessing the effects of a single dose of psilocybin on rumination in major depressive disorder.
Therapeutic Area
Therapeutic area intelligence for Major Depressive Disorder with 8 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.